Mycophenolate mofetil in renal, transplantation: 3-year results from the placebo-controlled trial

Transplantation

Volumn 68, Issue 3, 1999, Pages 391-396

  Behrend, M ^p   Grinyo, J ^a   Vanrenterghem, Yves ^b   Rodicio, J ^c   Albrechtsen, D ^d   Sadek, S ^e   Soulillou, J P ^f   Van Son, W ^g   Wagner, K ^h   Groth, C ⁱ   Mjornstedt L ^j   Wiesel, M ^p   Neumayer, H H ^k   Lang, P ^l   Tufveson, G ^p   Ekberg, H ^m   Tarantino, A ⁿ   Thiel, G ^p   Hene R ^p   Morgan, A ^p   Wang, W ^o   Ramos, E ^o   Rees, M ^o   more..

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h UNIVERSITY OF DUISBURG ESSEN   (Germany)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^k UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^l HENRI MONDOR HOSPITAL   (France)

^m LUND UNIVERSITY HOSPITAL   (Sweden)

ⁿ FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^o Roche Global Development   (United States)

^p NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANEMIA; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

EID: 0033567122     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199908150-00011     Document Type: Article

References (16)

1. Gulanikar AC, MacDonald AS, Sungertekin U, Belitsky P. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation 1992; 53: 323.
2. Almond PS, Matas AJ, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752.
3. Lindholm A, Ohlman S, Albrechtsen D, Tufveson G, Persson H, Persson NH. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 1993; 56: 307.
4. Tesi RJ, Henry ML, Elkammas EA, Ferguson RM. Predictors of long-term primary cadaveric renal transplant survival. Clin Transplant 1993; 7: 345.
5. Vanrenterghem Y. Acute rejection and renal allograft outcome. Nephrol Dial Transplant 1994; 10 (suppl 1): 29.
6. Allison AC, Eugui EM. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol 1993; 14: 353.
7. Allison AC, Eugui EM. Purine metabolism and the immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996; 10: 77.
8. Eugui EM, Allison AC. Immunosuppressive activity of mycophenolate mofetil. Ann NY Acad Sci 1993; 685: 308.
9. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 1: 1321.
10. Sollinger HW for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.
11. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
12. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C for the International Mycophenolate Mofetil Renal Transplant Study Groups. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 1997; 63: 39.
13. O'Gara MJ, Lee CH, Weinberg GA, Nott JM, Queener SF. IMP dehydrogenase from Pneumocystis carinii as a potential drug target. Antimicrob Agents Chemother 1997; 41: 40.
14. Allison AC, Eugui EM. Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc 1994; 26: 3205.
15. Azuma H, Binder J, Heemann U, Schmid C, Tullius SG, Tilney NL. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. Transplantation 1995; 59: 460.
16. O'Hair DP, McManus RP, Komorowski R. Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetil. Ann Thorac Surg 1994; 58: 1311.